A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic NSCLC - ARTEMIDE-01

Exclusion Criteria

• •Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion
• •Documented test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation)
• •Previous treatment with an anti-TIGIT therapy
• •Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
• •Part A and Part B: Primary or secondary resistance after treatment with 2 or more regiments including a CPI.
• •Part C and Part D: Any prior systemic treatment with an immune
• oncology agent (prior administration of immune-oncology agent for
• curative intent to treat other invasive malignancy is permitted).
• Treatment with one previous systemic chemotherapy will be allowed.
• •Primary or secondary resistance after treatment with 2 or more regimens including a CPI.
• •Symptomatic central nervous system (CNS) metastasis.
• •Thromboembolic event within 3 months prior to enrolment.
• •Other invasive malignancy within 2 years prior to screening.